Among 5‐, 8‐, and 10‐year OS as well as median survival time (MST) of NSCLC patients with higher PD‐L1 expression were significantly lower than those in the group with lower PD‐L1 expression (23.33% vs. 53.16%, 19.17% vs. 49.44%, 19.17% vs. 48.70%, 24 months vs. 55 months, p < 0.0001, Figure 2(a)). The gene discussed is CD274; the disease is non-small cell lung carcinoma.